TherapeuticsMD FY25 net loss from continuing operations narrows 73.91% to $0.7 million

Reuters03-31

TherapeuticsMD FY25 net loss from continuing operations narrows 73.91% to $0.7 million

TherapeuticsMD posted a net loss from continuing operations of $(0.7) million, narrowing by $1.7 million.
Revenue rose 71.6% to $3 million, driven by changes in sales of licensed products under Mayne License Agreement.
Total operating expenses declined 5.9% to $7.4 million.
Cash and cash equivalents totaled $7.5 million at year-end.
Strategic alternatives review continued, including potential acquisition, merger, business combination, or asset sale.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TherapeuticsMD Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603301605BIZWIRE_USPR_____20260330_BW300354) on March 30, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623326047?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 04:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623326047","market":"us","top_or_hot":-1,"title":"TherapeuticsMD FY25 net loss from continuing operations narrows 73.91% to $0.7 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TherapeuticsMD FY25 net loss from continuing operations narrows 73.91% to $0.7 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          TherapeuticsMD posted a net loss from continuing operations of $(0.7) million, narrowing by $1.7 million.\n        </li>\n<li>\n          Revenue rose 71.6% to $3 million, driven by changes in sales of licensed products under Mayne License Agreement.\n        </li>\n<li>\n          Total operating expenses declined 5.9% to $7.4 million.\n        </li>\n<li>\n          Cash and cash equivalents totaled $7.5 million at year-end.\n        </li>\n<li>\n          Strategic alternatives review continued, including potential acquisition, merger, business combination, or asset sale.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/TXMD\">TherapeuticsMD Inc.</a> published the original content used to generate this news brief via Business Wire (Ref. ID: 202603301605BIZWIRE_USPR_____20260330_BW300354) on March 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TherapeuticsMD FY25 net loss from continuing operations narrows 73.91% to $0.7 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTherapeuticsMD FY25 net loss from continuing operations narrows 73.91% to $0.7 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-31 04:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TherapeuticsMD FY25 net loss from continuing operations narrows 73.91% to $0.7 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          TherapeuticsMD posted a net loss from continuing operations of $(0.7) million, narrowing by $1.7 million.\n        </li>\n<li>\n          Revenue rose 71.6% to $3 million, driven by changes in sales of licensed products under Mayne License Agreement.\n        </li>\n<li>\n          Total operating expenses declined 5.9% to $7.4 million.\n        </li>\n<li>\n          Cash and cash equivalents totaled $7.5 million at year-end.\n        </li>\n<li>\n          Strategic alternatives review continued, including potential acquisition, merger, business combination, or asset sale.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/TXMD\">TherapeuticsMD Inc.</a> published the original content used to generate this news brief via Business Wire (Ref. ID: 202603301605BIZWIRE_USPR_____20260330_BW300354) on March 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL8qj1dl:1","article_id":"2623326047","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623326047","pubTimestamp":1774901266,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TherapeuticsMD posted a net loss from continuing operations of $(0.7) million, narrowing by $1.7 million.Revenue rose 71.6% to $3 million, driven by changes in sales of licensed products under Mayne License Agreement.Total operating expenses declined 5.9% to $7.4 million.Cash and cash equivalents totaled $7.5 million at year-end.Strategic alternatives review continued, including potential acquisition, merger, business combination, or asset sale.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","TXMD":"TherapeuticsMD Inc."},"translate_title":"TherapeuticsMD 2025财年持续运营净亏损收窄73.91%至70万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TXMD":0.9},"content_text":"TherapeuticsMD FY25 net loss from continuing operations narrows 73.91% to $0.7 million\n    \n\n\n          TherapeuticsMD posted a net loss from continuing operations of $(0.7) million, narrowing by $1.7 million.\n        \n\n          Revenue rose 71.6% to $3 million, driven by changes in sales of licensed products under Mayne License Agreement.\n        \n\n          Total operating expenses declined 5.9% to $7.4 million.\n        \n\n          Cash and cash equivalents totaled $7.5 million at year-end.\n        \n\n          Strategic alternatives review continued, including potential acquisition, merger, business combination, or asset sale.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TherapeuticsMD Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603301605BIZWIRE_USPR_____20260330_BW300354) on March 30, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623326047","isCrawlerRequest":true}